PTO/SB/08a(04-07)
Approved for use through 7/31/2006. OMB 0651-0031
US Patent & Trademark Office, U S DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket No: AC-43-US

Complete if Known

Application Number	10/573,516
Filing Date	March 27, 2006
First Named Inventor	Daniel Bur et al.
Art Unit	1625
Examiner Name	John Mabry

US PATENT DOCUMENTS

Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T[2]
		WO 99/40192	08-12-1999		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		AMES, R.S. et al., "Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14" Nature (1999), 401, pp. 282-286.	
		BERN, H.A. et al., "Neurohormones from fish tails: the caudal neurosecretory system. I. Urophysiology and the caudal neurosecretory system of fishes", Recent Prog. Horm. Res., (1985), 41, pp. 533-552.	
		BREU, V. et al., In vitro characterization of Ro-46-2005, a novel synthetic non-peptide antagonist of ET_A and ET_B receptors., FEBS Lett., (1993), 334, pp. 210-214.	
		CHEUNG, B.M. et al., "Plasma concentration of urotensin II is raised in hypertension", J. Hypertens., (2004), 22, pp. 1341-1344.	
		CLOZEL, M. et al., "Pharmacology of the Urotensin-II Receptor Antagonist ACT-058362: First Demonstration of a Pathophysiological Role of the Urotensin System", J. Pharmacol. Exp. Ther., (2004), 311, pp. 204-212.	
		DOUGLAS, S.A., et al., "Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey", Br. J. Pharmacol., (2000), 131, pp. 1262-1274.	
		DOUGLAS, S.A. et al., "Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate", J. Cardiovasc. Pharmacol., (2000), 36, Suppl 1:S163-S166.	
		GARLTON, J., et al., "Central effects of urotensin-II following ICV administration in rats", Psychopharmacology (Berlin), (2001), 155, pp. 426-433.	
		HELLER, J. et al., "Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension", J. Hepatol., (2002), 37, pp. 767-772.	
		LIU, Q. et al., "Identification of urotension II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14", Biochem. Biophys. Res. Commun., (1999), 266, pp. 174-178.	
		MALINOWSKI, M., et al., "A Convenient Preparation of 4-Pyridinamine Derivatives", J. Prakt, Chem., (1988), 330, pp. 154-158.	

EXAMINER /John Mabry/ (06/05/2009) **DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

PTO/SB/08a(04-07)
Approved for use through 7/31/2006 OMB 0651-0031
US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	Complete if Known
Application Number	10/573,516
Filing Date	March 27, 2006
First Named Inventor	Daniel Bur et al.
Art Unit	1625
Examiner Name	John Mabry

Sheet	2	of	2	Attorney Docket No: AC-43-US

		MORI, M. et al., "Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14)", Biochem. Biophys. Res. Commun., (1999), 265, pp.123-129.	
		"Protective Groups in Organic Synthesis", T.W. Greene, P.G.M. Wuts, Wiley-Interscience, (1999)	
		RUSSELL, F.D., et al., "Cardiostimulant effects of urotensin-II in human heart in vitro", Br. J. Pharmacol., (2001), 132, pp. 5-9.	
		SHENOUDA, S. et al., "Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma", J. Histochem. Cytochem, (2002), 50, pp. 885-889.	
		SILVESTRE, R.A., et al., "Inhibition of insulin release by urotensin II-a study on the perfused rat pancreas", Horm Metab Res, (2001), 33, pp. 379-381.	
		TAKAHASHI, K. et al., "Expression of utotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity b SW-13 adrenocortical carcinoma cells", Peptides, (2001), 22, pp. 1175-1179.	
		TAKAHASHI, K. et al., "Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II", Peptides, (2003), 24, pp. 301-306.	
		TOTSUNE, K. et al., "Role of urotensin II in patients on dialysis", Lancent, (2001), 358, pp. 810-811.	
		TOTSUNE, K. et al., "Increased plasma urotensin II levels in patients with diabetes mellitus" Clin. Sci., (2003), 104, pp. 1-5.	
		TSANDIS, A. et al., "Urotensin II stimulates collagen synthesis of cardiac fibroblasts and hypertrophic signaling in cardiomyocytes via G(alpha)q- and Ras-dependent pathways", J. Am. Coll. Cardiol., (2001), 37, p. 164A.	
		ZOU, Y. et al., "Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats" FEBS Lett., (2001), 508, pp. 57-60.	

EXAMINER /John Mabry/ (06/05/2009) **DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

· EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. · Applicant's unique citation designation number (optional). · Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./